Scientists hunt for clues to better treat aggressive breast cancer
NCT ID NCT06240195
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with metastatic triple-negative breast cancer who are already receiving the drug sacituzumab govitecan as part of their routine care. Researchers want to see how well the drug works in everyday practice and find biological markers (biomarkers) that predict which patients benefit most. About 60 participants will provide tumor tissue and blood samples for analysis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
"Regina Elena" National Cancer Institute
RECRUITINGRome, Rome, 00144, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••